Articles & guides — page 4

125 cited, vendor-independent pieces on the questions people actually ask — reconstitution and handling, half-lives, compound comparisons, and how to track a protocol. Research and education only; never dosing advice, never sourcing.

125 articles

Half-life & pharmacology2 min

SubQ vs IM injections explained

Subcutaneous versus intramuscular administration: the tissue layer each targets, how it changes the absorption curve, and why route appears in research protocols.

Concept / method
Half-life & pharmacology2 min

What are GLP-1 receptor agonists?

GLP-1 receptor agonists explained: what the incretin hormone GLP-1 does, what "agonist" means, and how modern versions are engineered to last for days.

Approved medicine
Half-life & pharmacology2 min

What are growth hormone secretagogues?

Growth-hormone secretagogues explained: the two receptor families (GHRH analogs and ghrelin/GHS agonists), why they are paired, and where each compound fits.

Concept / method
Compound overviews7 min

What is BPC-157?

BPC-157 explained with the primary literature: the pentadecapeptide’s structure, its proposed VEGFR2 angiogenic mechanism, and an honest look at an evidence base that is almost entirely preclinical.

Preclinical
Compound overviews4 min

What is TB-500?

TB-500 explained with the literature: how this thymosin β4 fragment sequesters actin to drive cell migration, and the crucial catch — the human trials tested eye drops, not muscle injections.

Preclinical
Compound overviews4 min

What is ipamorelin?

Ipamorelin explained with the literature: a five-amino-acid peptide that triggers a pulse of your own growth hormone, why "selective" is its whole story, and an honest look at a mostly preclinical evidence base.

Preclinical
Compound overviews4 min

What is CJC-1295?

CJC-1295 explained with the human data: a GHRH analog, the crucial DAC vs no-DAC fork, and the 2006 trial that measured a 6–8 day half-life and days-long IGF-1 rises in healthy adults.

Human clinical data
Compound overviews3 min

What is semaglutide?

Semaglutide explained plainly: how this GLP-1 medication mimics a gut hormone, what the big human trials actually showed (STEP 1: ~15% weight loss), and the brands it sells under.

Approved medicine
Compound overviews3 min

What is tirzepatide?

Tirzepatide explained plainly: the "twincretin" that hits two gut-hormone receptors, why it is called imbalanced, and what SURMOUNT-1 showed (up to ~21% weight loss).

Approved medicine
Compound overviews3 min

What is tesamorelin?

Tesamorelin explained: a stabilised GHRH analog and — unlike most peptides in its family — an FDA-approved medicine (Egrifta), with the HIV lipodystrophy trials that got it there.

Approved medicine
Compound overviews5 min

What is sermorelin?

Sermorelin explained: the shortest fully-active GHRH fragment, its history as the approved drug Geref, how it relates to CJC-1295, and its status today as a compounded peptide.

Human clinical data
Compound overviews3 min

What is HCG?

HCG explained: human chorionic gonadotropin, why it acts like luteinizing hormone, why it is dosed in International Units instead of milligrams, and its TRT-adjacent research context.

Approved medicine

Zyra Track is a research and educational utility. Nothing on this page is medical advice, a dosing recommendation, or an endorsement of any compound. We never sell or source compounds and refuse sourcing questions. Consult a qualified clinician for decisions about your health.